Peptide Plug

Age Verification

Peptide Plug is a research and organization tool intended for adults 18 years of age or older. By continuing, you confirm you are at least 18.

Reference only · Not medical advice · For adults 18+ · No dosing information is published here
Peptide Plug
HomeResearchEducationToolsGuidesCompareAboutOpen the App
Home/Research library/Igf-1 Lr3
Muscle & Performance

Igf-1 Lr3 — reference

A modified IGF-1 analogue altered to resist binding proteins, greatly extending its activity relative to native IGF-1.

Regulatory statusNot FDA-Approved
Published half-life~20–30 hours
Evidence levelPK study
CategoryMuscle & Performance

Regulatory status

Not FDA-Approved. Not approved for human use anywhere. Sold as a research chemical. Banned by WADA.

Reported cautions

⚠ Worth knowing. Hypoglycemia is the immediate risk — IGF-1 has insulin-like activity and the LR3 modification makes it act far longer than the native peptide. Because IGF-1 promotes cell proliferation, existing or undiagnosed malignancy is the commonly cited contraindication.

Pharmacokinetics

Published figures give an elimination half-life of ~20–30 hours. The Long-R3 modification reduces IGF-binding-protein affinity, extending half-life well beyond native IGF-1's ~10–30 min.

This figure is tagged PK study in our evidence system. This figure comes from a published pharmacokinetic study rather than a label or registration trial. Sample sizes in such studies are often small and figures vary between them, so treat the number as a range rather than a constant. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.

Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →

What Peptide Plug does and does not publish

This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.

Frequently asked

Is Igf-1 Lr3 FDA-approved?
Not FDA-Approved. Not approved for human use anywhere. Sold as a research chemical. Banned by WADA.
What is the half-life of Igf-1 Lr3?
Published figures give ~20–30 hours. The Long-R3 modification reduces IGF-binding-protein affinity, extending half-life well beyond native IGF-1's ~10–30 min.
How reliable is that half-life figure?
It is tagged “PK study” in our system. This figure comes from a published pharmacokinetic study rather than a label or registration trial. Sample sizes in such studies are often small and figures vary between them, so treat the number as a range rather than a constant.
What cautions are associated with Igf-1 Lr3?
Hypoglycemia is the immediate risk — IGF-1 has insulin-like activity and the LR3 modification makes it act far longer than the native peptide. Because IGF-1 promotes cell proliferation, existing or undiagnosed malignancy is the commonly cited contraindication.
Does Peptide Plug publish dosing for Igf-1 Lr3?
No. This library publishes regulatory status, general context and pharmacokinetics only. Dose, frequency and cycle information is deliberately absent from these public pages — those are clinical decisions, not reference data.
Does Peptide Plug sell Igf-1 Lr3?
No. We do not sell, supply, source or link to vendors for any compound, and we have no affiliate arrangements with suppliers. Peptide Plug is a tracking and calculation tool.

Related tools

Free, no account required.

Half-Life Visualizer
Estimated rise-and-fall curve between doses.
Reconstitution Calculator
Vial math including blend support.
Medication Storage Calculator
Discard windows from published guidance.
Half-Life Data Table
All 86 compounds with evidence tags.
Pro Protocol Reference

The public research page intentionally does not publish dosing. Pro subscribers can open the separate Protocol Library for structured indication, frequency, duration, notes, and review-first Cycle Builder import when a matching reference is available.

View Protocol Reference
Reference information, not medical advice. This page describes regulatory status and published pharmacokinetics. It does not tell you whether to use this compound, how much to use, how often, or whether it is safe for you. Peptide Plug does not sell, supply or source any compound. Those decisions belong to you and a licensed clinician.

Part of the Peptide Plug research library · How we source our figures · All compounds A–Z